TSG-6 Inhibits Oxidative Stress and Induces M2 Polarization of Hepatic Macrophages in Mice With Alcoholic Hepatitis via Suppression of STAT3 Activation

Wan, Yue-Meng; Wu, Hua‐Mei; Li, Yuhua; Yang, Jinhui; Liu, Chang; He, Yuefeng; Wang, Men-Jie; Wu, Xinan; Zhang, Yuan

doi:10.3389/fphar.2020.00010

Cited by 26 publications

(15 citation statements)

References 31 publications

(63 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Upon activation, GLP-1R promotes cAMP production by adenylate cyclase, while enhancing glucosestimulated insulin secretion (34,35). Shiraishi et al (14) showed that stimulating RAW264.7 human monocyte-derived macrophage cells with GLP-1 in vitro resulted in upregulated surface expression of CD163 and CD204, increased IL-10 secretion, and activated the STAT3 pathway, one of the main signaling pathways related to macrophage polarization towards the M2 phenotype (36)(37)(38). Macrophage polarization is a highly plastic physiological process that responds to a variety of factors, by changing macrophage phenotype and function (39).…”

Section: Discussionmentioning

confidence: 99%

Glucagon-Like Peptide-1 Receptor Regulates Macrophage Migration in Monosodium Urate-Induced Peritoneal Inflammation

et al. 2022

View full text Add to dashboard Cite

Glucagon-like peptide-1 (GLP-1) is an insulinotropic peptide that signals through the GLP-1 receptor (GLP-1R). GLP-1R, therefore, plays a critical role in diabetes and cardiovascular disease. Whether GLP-1R is involved in inflammatory disease such as gout remains unclear. Macrophages are critical effector cells in the pathogenesis of gout, a common form of inflammatory arthritis caused by the deposition of uric acid in joints. The expression of GLP-1R at the protein level is controversial due to the lack of specificity of existing antibodies against GLP-1R. Using a transgenic mouse model expressing enhanced green fluorescent protein (EGFP) under the control of GLP-1R promoter, here we confirmed the expression of GLP-1R by macrophages. M2 type macrophages and Ly6C+ macrophages expressed higher levels of GLP-1R, compared to their counterparts. GLP-1R deficient macrophages displayed a reduced the migratory ability and an enhanced expression of interleukin (IL)-6, while the expression of IL-1β was not affected. In monosodium urate (MSU) crystal-induced peritonitis, an experimental model of gout, the recruitment of macrophages, especially M2 macrophages, was significantly suppressed in GLP-1R knockout mice compared to wild-type mice. In conclusion, our data suggests that GLP-1R plays a critical role in macrophage migration in MSU-induced inflammation.

show abstract

Section: Discussionmentioning

confidence: 99%

Glucagon-Like Peptide-1 Receptor Regulates Macrophage Migration in Monosodium Urate-Induced Peritoneal Inflammation

et al. 2022

View full text Add to dashboard Cite

show abstract

“…VK2 vaginal epithelial ( Figure 7 ) and End1 endocervical epithelial ( Supplementary Figure 6 ) cells exposed to TP4 showed upregulation of TSG-6, which activated STAT6 in macrophages. TSG-6 has been considered as a therapeutic target in many inflammation-related diseases, including atherosclerosis ( 50 ), osteoarthritis ( 51 ), acute myocardial infarction ( 52 ), subarachnoid hemorrhage-induced early brain injury ( 53 ), inflammatory lung injury ( 54 ), and alcoholic hepatitis ( 55 ). In addition to its anti-inflammatory activity, TSG-6 also exhibits tissue-protective activity ( 56 ).…”

Section: Discussionmentioning

confidence: 99%

Tilapia Piscidin 4 (TP4) Reprograms M1 Macrophages to M2 Phenotypes in Cell Models of Gardnerella vaginalis-Induced Vaginosis

Liu

Chen

2021

Front. Immunol.

View full text Add to dashboard Cite

Gardnerella vaginalis is associated with bacterial vaginosis (BV). The virulence factors produced by G. vaginalis are known to stimulate vaginal mucosal immune response, which is largely driven by activated macrophages. While Tilapia piscidin 4 (TP4), an antimicrobial peptide isolated from Nile tilapia, is known to display a broad range of antibacterial functions, it is unclear whether TP4 can affect macrophage polarization in the context of BV. In this study, we used the culture supernatants from G. vaginalis to stimulate differentiation of THP-1 and RAW264.7 cells to an M1 phenotype. The treatment activated the NF-κB/STAT1 signaling pathway, induced reactive nitrogen and oxygen species, and upregulated inflammatory mediators. We then treated the induced M1 macrophages directly with a non-toxic dose of TP4 or co-cultured the M1 macrophages with TP4-treated vaginal epithelial VK2 cells. The results showed that TP4 could not only decrease pro-inflammatory mediators in the M1 macrophages, but it also enriched markers of M2 macrophages. Further, we found that direct treatment with TP4 switched M1 macrophages toward a resolving M2c phenotype via the MAPK/ERK pathway and IL-10-STAT3 signaling. Conversely, tissue repair M2a macrophages were induced by TP4-treated VK2 cells; TP4 upregulated TSG-6 in VK2 cells, which subsequently activated STAT6 and M2a-related gene expression in the macrophages. In conclusion, our results imply that TP4 may be able to attenuate the virulence of G. vaginalis by inducing resolving M2c and tissue repair M2a macrophage polarizations, suggesting a novel strategy for BV therapy.

show abstract

“…This makes them an attractive receptor to be targeted in cancer therapy using RGD peptide [ 133 ]. Recently, Yan and coworkers reported on dual ligand using RGD peptide and folic acid functionalized MSNs to target human breast cancer MCF-7 cell [ 164 ]. Similar to previous reports, peptide-containing RGD motif was used as both the gate to cover the MSNs pores and targeting agent [ 165 ].…”

Section: Msns As Smart Drug Delivery Agentmentioning

confidence: 99%

Progress in Mesoporous Silica Nanoparticles as Drug Delivery Agents for Cancer Treatment

et al. 2021

View full text Add to dashboard Cite

Cancer treatment and therapy have made significant leaps and bounds in these past decades. However, there are still cases where surgical removal is impossible, metastases are challenging, and chemotherapy and radiotherapy pose severe side effects. Therefore, a need to find more effective and specific treatments still exists. One way is through the utilization of drug delivery agents (DDA) based on nanomaterials. In 2001, mesoporous silica nanoparticles (MSNs) were first used as DDA and have gained considerable attention in this field. The popularity of MSNs is due to their unique properties such as tunable particle and pore size, high surface area and pore volume, easy functionalization and surface modification, high stability and their capability to efficiently entrap cargo molecules. This review describes the latest advancement of MSNs as DDA for cancer treatment. We focus on the fabrication of MSNs, the challenges in DDA development and how MSNs address the problems through the development of smart DDA using MSNs. Besides that, MSNs have also been applied as a multifunctional DDA where they can serve in both the diagnostic and treatment of cancer. Overall, we argue MSNs provide a bright future for both the diagnosis and treatment of cancer.

show abstract

TSG-6 Inhibits Oxidative Stress and Induces M2 Polarization of Hepatic Macrophages in Mice With Alcoholic Hepatitis via Suppression of STAT3 Activation

Cited by 26 publications

References 31 publications

Glucagon-Like Peptide-1 Receptor Regulates Macrophage Migration in Monosodium Urate-Induced Peritoneal Inflammation

Glucagon-Like Peptide-1 Receptor Regulates Macrophage Migration in Monosodium Urate-Induced Peritoneal Inflammation

Tilapia Piscidin 4 (TP4) Reprograms M1 Macrophages to M2 Phenotypes in Cell Models of Gardnerella vaginalis-Induced Vaginosis

Progress in Mesoporous Silica Nanoparticles as Drug Delivery Agents for Cancer Treatment

Contact Info

Product

Resources

About